Effect of Very High-Intensity Statin Therapy on Regression of Coronary Athero…

Very high-intensity statin therapy using rosuvastatin 40 mg/d achieved an average LDL-C of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in significant regression of atherosclerosis for all 3 prespecified IVUS measures of disease burden. Treatment to LDL-C levels below currently accepted guidelines, when accompanied by significant HDL-C increases, can regress atherosclerosis in coronary di…

Rosuvastatin in Older Patients with Systolic Heart Failure

Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients

Primary prevention of cardiovascular disease with atorvastatin in type 2 diab…

Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid-lowering therapy with statins for the primary prevention of cardiovascular disease in diabetes is inadequately defined. We aimed to assess the effectiveness of atorvastatin 10 mg daily for primary prevention of major cardiovascular events in patients with type 2 diabetes without hi…

Prevention of coronary and stroke events with atorvastatin in hypertensive pa…

The lowering of cholesterol concentrations in individuals at high risk of cardiovascular disease improves outcome. No study, however, has assessed benefits of cholesterol lowering in the primary prevention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed dyslipidaemic

Comparative in-vitro activity of cefpirome againts isolates from intensive ca…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Randomized comparative trial of cefpirome versus ceftazidime in the empirical…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Comparison of Strategies Using Cefpirome and Ceftazidime for Empiric Treatmen…

In an international, multicenter, open-label, randomized comparative study, adult patients in intensive care units were enrolled to receive cefpirome intravenously at 2 g twice daily or ceftazidime intravenously at 2 g three times daily for the empiric treatment of pneumonia. Randomization was performed after a double stratification according to the investigator’s initial choice of monothe…

Cefpirome: a review of its antibacterial activity, pharmacokinetic properties…

Cefpirome is an injectable extended-spectrum or 'fourth generation ' cephalosporin. Its antibacterial activity encompasses many ofthe pathogens involved in hospital-acquired infections such as Enterobacteriaceae, methicillin-susceptible Staphylococcus aureus , coagulase-negative staphylococci and viridans group streptococci. Cefpirome also has in vitro activity against Streptococcus pneumoni…

Effect of meloxicam on postoperative pain after abdominal hysterectomy

We studied 36 patients, allocated randomly to receive meloxicam 15 mg rectally (n
18) or placebo suppository (n
18) before total abdominal hysterectomy in a double-blind study. Visual analogue scores for pain at rest (P0.005), on movement (P0.05) and on coughing (P0.05) were significantly decreased in the meloxicam group during the first 24 h after surgery. Mean 24-h PCA morphine requirement…

Role of favipiravir in the treatment of COVID-19

The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro ac…